Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Pharmaceutical Outsourcing Present and Future

The need for preclinical testing expertise is growing as molecular complexity increases.

Navigating the Preclinical CRO Outsourcing Process

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

A Closer Look at Affinity Ligands

Topic

Articles

Tom Sellig, Adare Pharma Solutions, shares how the CDMO is positioning for growth amid US reshoring and oral dose innovation trends.

Tom Sellig on CDMO Innovation and US Manufacturing Growth

Erez Israeli is chief executive officer of Dr. Reddy's Laboratories.

Erez Israeli, chief executive officer of Dr. Reddy's Laboratories, provides insight on the company’s generic version of semaglutide, which entered the Canadian market in May 2026.

Generic GLP-1s Enter Canadian Market

Dr. Christine Allen is co-founder and CEO of Intrepid Labs. Dr. Allen is an internationally recognized expert in drug formulation and development, with over 200 peer-reviewed publications. She is a Professor at the University of Toronto and a Fellow of both the American Institute for Medical and Biological Engineering and the Canadian Academy of Health Sciences. She has held numerous leadership roles across academia and industry, including President of the Controlled Release Society and Editor-in-Chief of the 

Dr. Andrew Lewis is Chief Scientific Officer of Quotient Sciences. As the leader of Quotient Sciences' scientific teams and drug development consultants, Dr. Lewis is responsible for driving efficiency and innovation within our scientific organization, both to better serve our customers and drive growth for the Company.

Andy has over 25 years of experience in the pharmaceutical and drug delivery industry and is a member of the Academy of Pharmaceutical Scientists of Great Britain. Additionally, Andy has served on the board of directors of the Controlled Release Society, most recently as secretary.

Prior to joining Quotient Sciences, Andy was Director of Novel Drug Delivery Technologies at Ipsen. He holds a Ph.D. in Tissue Engineering and a Bachelor of Pharmacy, both from the University of Nottingham.

Dr. Christine Allen, Co-Founder and CEO of Intrepid Labs, and Dr. Andrew Lewis, Chief Scientific Officer of Quotient Sciences, explain how AI can be used in drug development to shorten development timelines. 

Pharma Fundamentals: Utilizing Artificial Intelligence in Drug Development

Ranjit Deshmukh is Principal at BiologixCMC.

Videos

Ranjit Deshmukh, Principal, BiologixCMC, discusses how contract manufacturers can optimize their processes and plan for the future by optimizing facility design. 

Facility Design for Optimized Contract Manufacturing

Asahi Kasei acquires Aicuris, adding three antiviral assets targeting immunocompromised patients, with combined revenue projected at $500M by 2030.

Asahi Kasei's Aicuris Acquisition Targets Infectious Disease Therapies

Melanie Cerullo is chief quality officer at Kindeva.

Contract development and manufacturing organizations can assist the sponsor company in ensuring sterility assurance in alignment with the EU’s Annex 1 guidelines.

Is Your Annex 1 Strategy a Static Document or a Dynamic Defense?

SGD Pharma and Prince launch sterile Type I glass nasal vials for the US market, targeting complex chronic conditions like Alzheimer's and Parkinson's.

SGD Pharma Launches Sterile Nasal Vial Platform for US Market

The two companies have entered into a licensing agreement to commercialize biosimilars in Latin America.

SteinCares and Shilpa Biologicals Collaborate on Biosimilar Access for Latin America

The companies have extended a commercial supply partnership for the manufacture of Sohonos (palovarotene), which is a treatment for the ultra-rare disease, fibrodysplasia ossificans progressiva.

Quotient Sciences Extends Partnership with Ipsen for Manufacture of Ultra-Rare Disease Treatment

Lars Hahn is senior vice-president, Global Sales Organization, at Vetter.

Trust-based CDMO partnerships are becoming essential to accelerate injectable drug development, manage risk, and ensure resilient biopharma supply.